PT2722341T - Anticorpos contra interleucina-6 e utilizações dos mesmos - Google Patents
Anticorpos contra interleucina-6 e utilizações dos mesmosInfo
- Publication number
- PT2722341T PT2722341T PT131894222T PT13189422T PT2722341T PT 2722341 T PT2722341 T PT 2722341T PT 131894222 T PT131894222 T PT 131894222T PT 13189422 T PT13189422 T PT 13189422T PT 2722341 T PT2722341 T PT 2722341T
- Authority
- PT
- Portugal
- Prior art keywords
- interleukin
- antibodies
- Prior art date
Links
- 102000004889 Interleukin-6 Human genes 0.000 title 1
- 108090001005 Interleukin-6 Proteins 0.000 title 1
- 229940100601 interleukin-6 Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261716802P | 2012-10-22 | 2012-10-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2722341T true PT2722341T (pt) | 2018-03-12 |
Family
ID=49385162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT131894222T PT2722341T (pt) | 2012-10-22 | 2013-10-18 | Anticorpos contra interleucina-6 e utilizações dos mesmos |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US9234035B2 (pt) |
| EP (1) | EP2722341B1 (pt) |
| JP (1) | JP6469012B2 (pt) |
| KR (1) | KR102321372B1 (pt) |
| CN (1) | CN103772503B (pt) |
| AU (1) | AU2013335004B2 (pt) |
| CA (1) | CA2889181C (pt) |
| DK (1) | DK2722341T3 (pt) |
| ES (1) | ES2662020T3 (pt) |
| IL (1) | IL238366B (pt) |
| PT (1) | PT2722341T (pt) |
| RU (1) | RU2656162C2 (pt) |
| TW (1) | TWI500629B (pt) |
| WO (1) | WO2014066167A1 (pt) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2656162C2 (ru) | 2012-10-22 | 2018-05-31 | Фоунтейн Биофарма Инк. | Антитела к интерлейкину 6 и их применение |
| CN105198982B (zh) * | 2014-06-18 | 2019-07-26 | 上海交通大学 | 基于il-6的抗原表位及其应用 |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| RU2744860C2 (ru) | 2015-12-30 | 2021-03-16 | Кодиак Сайенсиз Инк. | Антитела и их конъюгаты |
| CN109867723B (zh) * | 2017-12-05 | 2022-06-17 | 南京金斯瑞生物科技有限公司 | 抗人il6单克隆抗体及其制备方法和用途 |
| MX2020009152A (es) * | 2018-03-02 | 2020-11-09 | Kodiak Sciences Inc | Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos. |
| CN109517064B (zh) * | 2018-10-10 | 2020-05-08 | 北京汇智和源生物技术有限公司 | 白介素-6的人源化单克隆抗体、其编码基因及应用 |
| AU2020364071A1 (en) | 2019-10-10 | 2022-05-26 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| WO2023042314A1 (ja) * | 2021-09-15 | 2023-03-23 | 和幸 吉崎 | 免疫異常性炎症性疾患を治療または予防するための組成物 |
| WO2023042209A2 (en) | 2021-09-20 | 2023-03-23 | Yeda Research And Development Co. Ltd. | Treatment of myeloid malignancies |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5354844A (en) | 1989-03-16 | 1994-10-11 | Boehringer Ingelheim International Gmbh | Protein-polycation conjugates |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US5527528A (en) | 1989-10-20 | 1996-06-18 | Sequus Pharmaceuticals, Inc. | Solid-tumor treatment method |
| GB9022543D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
| US6136310A (en) | 1991-07-25 | 2000-10-24 | Idec Pharmaceuticals Corporation | Recombinant anti-CD4 antibodies for human therapy |
| US5648267A (en) | 1992-11-13 | 1997-07-15 | Idec Pharmaceuticals Corporation | Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same |
| AU2002346369B2 (en) * | 2001-11-14 | 2009-08-27 | Eusa Pharma (Uk) Ltd | Anti-IL-6 antibodies, compositions, methods and uses |
| JP4463104B2 (ja) * | 2002-08-30 | 2010-05-12 | 財団法人化学及血清療法研究所 | ヒト抗ヒトインターロイキン−６抗体及び該抗体フラグメント |
| PE20061324A1 (es) * | 2005-04-29 | 2007-01-15 | Centocor Inc | Anticuerpos anti-il-6, composiciones, metodos y usos |
| EP2439272A3 (en) * | 2005-05-09 | 2013-07-31 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| EP2314626A1 (en) * | 2005-12-09 | 2011-04-27 | UCB Pharma, S.A. | Antibody molecules having specificity for human IL-6 |
| MX2009001110A (es) | 2006-08-03 | 2009-05-11 | Vaccinex Inc | Anticuerpos monoclonales anti-il-6 y usos de los mismos. |
| TW200831528A (en) * | 2006-11-30 | 2008-08-01 | Astrazeneca Ab | Compounds |
| US8188235B2 (en) * | 2008-06-18 | 2012-05-29 | Pfizer Inc. | Antibodies to IL-6 and their uses |
| CN102245207B (zh) | 2008-11-13 | 2015-11-25 | 费塔制药股份有限公司 | 人源化抗il-6抗体 |
| AU2009323002B2 (en) * | 2008-11-25 | 2016-01-28 | Vitaeris Inc. | Antagonists of IL-6 to raise albumin and/or lower CRP |
| AU2010208125B2 (en) * | 2009-01-29 | 2015-02-12 | Medimmune, Llc | Human anti-IL-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases |
| EP2516467A2 (en) * | 2009-12-23 | 2012-10-31 | Emergent Product Development Seattle, LLC | Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof |
| JP4934207B2 (ja) * | 2010-01-28 | 2012-05-16 | セントカー・インコーポレーテツド | 抗ｉｌ−６抗体、組成物、方法および使用 |
| ES2899186T3 (es) | 2010-12-31 | 2022-03-10 | Bioatla Inc | Humanización rápida de anticuerpos |
| RU2656162C2 (ru) | 2012-10-22 | 2018-05-31 | Фоунтейн Биофарма Инк. | Антитела к интерлейкину 6 и их применение |
-
2013
- 2013-10-18 RU RU2015119159A patent/RU2656162C2/ru active
- 2013-10-18 US US14/057,349 patent/US9234035B2/en active Active
- 2013-10-18 KR KR1020157013100A patent/KR102321372B1/ko active IP Right Grant
- 2013-10-18 TW TW102137767A patent/TWI500629B/zh active
- 2013-10-18 DK DK13189422.2T patent/DK2722341T3/en active
- 2013-10-18 WO PCT/US2013/065668 patent/WO2014066167A1/en active Application Filing
- 2013-10-18 EP EP13189422.2A patent/EP2722341B1/en active Active
- 2013-10-18 ES ES13189422.2T patent/ES2662020T3/es active Active
- 2013-10-18 PT PT131894222T patent/PT2722341T/pt unknown
- 2013-10-18 AU AU2013335004A patent/AU2013335004B2/en active Active
- 2013-10-18 JP JP2015539676A patent/JP6469012B2/ja active Active
- 2013-10-18 CA CA2889181A patent/CA2889181C/en active Active
- 2013-10-18 CN CN201310492386.8A patent/CN103772503B/zh active Active
-
2015
- 2015-04-19 IL IL238366A patent/IL238366B/en active IP Right Grant
- 2015-12-31 US US14/985,642 patent/US9758580B2/en active Active
-
2017
- 2017-08-25 US US15/687,085 patent/US10370443B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| TWI500629B (zh) | 2015-09-21 |
| KR20150085816A (ko) | 2015-07-24 |
| US20170362317A1 (en) | 2017-12-21 |
| CN103772503B (zh) | 2017-05-10 |
| WO2014066167A1 (en) | 2014-05-01 |
| KR102321372B1 (ko) | 2021-11-11 |
| TW201429988A (zh) | 2014-08-01 |
| US9234035B2 (en) | 2016-01-12 |
| AU2013335004A1 (en) | 2015-05-14 |
| US20140112935A1 (en) | 2014-04-24 |
| IL238366A0 (en) | 2015-06-30 |
| AU2013335004B2 (en) | 2018-06-28 |
| ES2662020T3 (es) | 2018-04-05 |
| RU2015119159A (ru) | 2016-12-20 |
| US10370443B2 (en) | 2019-08-06 |
| RU2656162C2 (ru) | 2018-05-31 |
| EP2722341A1 (en) | 2014-04-23 |
| US9758580B2 (en) | 2017-09-12 |
| CA2889181A1 (en) | 2014-05-01 |
| EP2722341B1 (en) | 2017-12-06 |
| CA2889181C (en) | 2021-12-07 |
| CN103772503A (zh) | 2014-05-07 |
| US20160185851A1 (en) | 2016-06-30 |
| DK2722341T3 (en) | 2018-03-12 |
| IL238366B (en) | 2018-06-28 |
| JP2016501837A (ja) | 2016-01-21 |
| JP6469012B2 (ja) | 2019-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1207092A1 (en) | Anti-hla-b27 antibodies and uses thereof -hla-b27 | |
| IL238559B (en) | Antibodies against ceacam5 and their use | |
| HK1212034A1 (en) | Antibodies to risperidone and use thereof | |
| HRP20190358T1 (hr) | Antitijela protiv asic1 i njihova primjena | |
| HK1211958A1 (en) | Antibodies to paliperidone and use thereof | |
| HK1212033A1 (en) | Antibodies to olanzapine and use thereof | |
| IL238366A0 (en) | Antibodies to interleukin-6 and their uses | |
| EP2888373A4 (en) | ANTIBODIES DIRECTED AGAINST ARIPIPRAZOLE AND THEIR USE | |
| GB201208372D0 (en) | Antibodies and uses thereof |